The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Stephen Samuel OpatAlessandra TedeschiKim LintonPamela McKayBei HuHenry ChanJie JinMagdalena Sobieraj-TeaguePier Luigi Luigi ZinzaniMorton ColemanCatherine ThieblemontPeter BrowettXiaoyan KeMingyuan SunRobert MarcusCraig A PortellKirit M ArdeshnaFontanet BijouPatricia WalkerEliza A HawkesSally MappShir-Jing HoDipti TalaulikarKe-Shu ZhouMelannie CoXiaotong LiWenxiao ZhouMassimo CappelliniChris TankersleyJane HuangJudith TrotmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Zanubrutinib demonstrated high ORR and CR rate with durable disease control and a favorable safety profile in patients with R/R MZL.